Notice for tozinameran and famtozinameran (Pfizer Australia Pty Ltd)
Active ingredients
tozinameran and famtozinameran
Sponsor
Date of review outcome
Lapse date
Type
Provisional determination
Indication
As a booster dose for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 months to < 5 years of age
Therapeutic area
Infectious diseases